Nautilus Biotechnology will receive up to $6 million over four years as part of the ARPA-H-funded SEEDS consortium to use its Voyager Platform for studying proteoforms linked to Alzheimer’s disease and Ewing sarcoma. This research aims to better understand protein misfolding that causes neurodegenerative diseases and cancer, enabling earlier detection and treatment. The Voyager Platform analyzes proteins at a single-molecule level, generating data to train AI models for predicting disease progression. This collaboration could lead to new diagnostics and therapies targeting protein dysfunction at early stages.
Nautilus Biotechnology's new research funding is noted alongside Pluang's health sector market snapshot as of Oct 27, 2026 16:11 WIB: out of 150 priced health-sector US stocks, 61 rose and 75 fell. Among notable movers, NUWE (Nuwellis Inc) rose 4.90% to USD 3.21 with a typical hold time of 29 days and a Pluang order activity skewed 94% Sell / 6% Buy, AMWL (American Well Corp) increased 4.87% to USD 14.20 with a 62-day hold time, while MRVI (Maravai LifeSciences Holdings Inc. Class A Common Stock) declined 4.75% to USD 7.22 with an 8-day hold time.
CareCloud has named Mitchell Brie as Chief Compliance Officer to lead its growing healthcare compliance business. Brie, founder of Empower Healthcare & Compliance Partners (acquired by CareCloud), will oversee corporate compliance and continue as Pre...
eSoftware Associates advises defense contractors to carefully map controlled unclassified information (CUI) access permissions before licensing Microsoft 365 Copilot in the GCC High cloud environment. Moving to GCC High does not automatically grant c...
Man Group PLC has publicly disclosed holding a 5.64% interest in Vesuvius plc, including direct shares and cash-settled derivatives. This disclosure is related to an ongoing offer involving RHI Magnestia N.V., which is also named in the filing. The d...
Nautilus Biotechnology announced its Q3 2026 financial results, reporting $0.2 million in revenue mainly from grants and early access services, and a net loss of $15.6 million. The company highlighted progress in its proteome analysis platform, inclu...
Eviden, part of Atos Group, has introduced ASTRA-LAS, a tactical decision-support solution designed to aid naval officers in complex maritime environments. The system uses operational data and AI to enhance situational awareness, reduce cognitive loa...
